Amgen Inc (NASDAQ: AMGN) has reported E.P.S. of $1.39 for its second fiscal quarter (ending June 30) versus $2.58 for the same period a year ago — a decline of -46%. Relative to the consensus estimate of $5.00, this was a shortfall of $-3.61. For the latest four quarters through June 30, E.P.S. were $5.84 compared to $14.93 a year ago — a decline of -61%.
Recent Price Action
Amgen Inc (NASDAQ: AMGN) stock closed at $328.95 on 8/6/24 after an increase of 1.1%. NORMAL trading volume accompanied the advance. The stock has declined -1.1% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, AMGN is expected to continue to be a major Value Builder.
Amgen has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Amgen has a slightly positive Power Rating of 61 and a good Appreciation Score of 81, and the Highest Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment